Valeant sets sights on Zoetis; Report: VC cash follows male boards and CEOs;

@FierceBiotech: Harvard team makes 'sweating' vehicles for liquid drug delivery. FierceDrugDelivery story | Follow @FierceBiotech

@JohnCFierce: Big story yesterday: Bristol-Myers rips up its R&D group, adding, eliminating and moving 800-plus Hubs win. Report | Follow @JohnCFierce

@DamianFierce: From BIO last week, here's $QURE CEO Aldag talking about $CLDN, $AAVL and the future of gene therapy. Listen | Follow @DamianFierce

> The boards of successful biotech companies remain overwhelming male-dominated, according to a new report from Liftstream examining the gender constitution of drug developers that get venture financing. More

> Eli Lilly ($LLY) and Adocia are heralding success in a Phase Ib trial of a fast-acting insulin. News

> Valeant ($VRX) is reportedly bidding for Zoetis ($ZTS), the animal health-focused company that spun off from Pfizer ($PFE) in 2013. Story

Medical Device News

@FierceMedDev: Cinven snatches up Synlab for $1.96B to beef up in diagnostics. FierceDiagnostics news | Follow @FierceMedDev

@VarunSaxena2: Valeant makes offer for Zoetis, sources tell WSJ. FiercePharma story | Follow @VarunSaxena2

@EmilyWFierce: $ILMN just signed a 20-year lease for a new 155,000 square foot scientific research building in England. Release | Follow @EmilyWFierce

> BlackBerry unveils plans for bacteria-free smartphone device. More

> European researchers develop thought-controlled robot. Article

Pharma News

@FiercePharma: Egg prices soar, menu items dropped in wake of historic avian flu. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: France's TxCell closes its plant at ANSM urging to avoid contamination. FiercePharmaManufacturing article | Follow @EricPFierce

> Nurse pleads guilty to taking Insys kickbacks as Subsys marketing probe continues. Report

> Sanofi's Brandicourt faces skeptical unions, anxious shareholders. Story

> Valeant makes offer for Zoetis, sources tell WSJ. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.